Unlocking the Potential of CA11 (CARPX1) as a Drug Target and Biomarker

Target Name: CA11

NCBI ID: G770

CA11

Unlocking the Potential of CA11 (CARPX1) as a Drug Target and Biomarker

CA11 (Carpx1) is a protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. Its function is not well understood, but it is known to be involved in several cellular processes, including cell adhesion, migration, and invasion.Recent studies have identified CA11 as a potential drug target and biomarker, with potential utility in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the potential of CA11 as a drug target and biomarker, with a focus on its involvement in cancer and neurodegenerative diseases.

CA11 as a Drug Target

Carpx1 has been identified as a potential drug target due to its unique structure and its ability to interact with various signaling pathways. The protein is composed of a N-terminus that contains a putative transmembrane domain, a middle tier that includes a cytoplasmic domain, and an C-terminus that contains a extracellular domain. The cytoplasmic domain is thought to play a key role in the protein's intracellular localization and stability, while the extracellular domain is involved in its interactions with ligands and other proteins.

Several studies have shown that CA11 can interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. These interactions suggest that CA11 may be involved in the regulation of cellular processes that are important for human health and disease, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of CA11 as a drug target is its potential to target various types of cancer, including breast, ovarian, and colorectal cancer. These cancers are often characterized by the production of elevated levels of angiogenesis factors, which are promoting the growth and survival of cancer cells. By targeting CA11, researchers may be able to inhibit the formation of these angiogenesis factors and reduce the growth and spread of cancer cells.

In addition to its potential as a cancer drug target, CA11 has also been identified as a potential biomarker for several types of cancer, including breast and ovarian cancer. This is because the expression of CA11 is often increased in these cancers, and may be used as a diagnostic or predictive marker for the disease.

CA11 as a Neurodegenerative Disease Biomarker

Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurodegeneration. These diseases are often treated with drugs that aim to slow down or halt the progression of neurodegeneration, but there is a need for better diagnostic tools to identify and diagnose the disease at an early stage.

CA11 has been shown to be involved in the regulation of cellular processes that are important for the development and progression of neurodegenerative diseases. Several studies have shown that the expression of CA11 is often increased in the brains of individuals with neurodegenerative diseases, and that it may be a useful biomarker for the disease.

One of the most promising aspects of CA11 as a neurodegenerative disease biomarker is its potential to diagnose the disease at an early stage. By targeting CA11, researchers may be able to identify individuals at risk for neurodegenerative diseases and start interventions early, before the disease progresses to a more advanced stage.

In addition to its potential as a diagn

Protein Name: Carbonic Anhydrase 11

Functions: Does not have a catalytic activity

The "CA11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CA11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets